Seeking Alpha initiated coverage on Summit Therapeutics with a cautious Buy rating.
The analysis describes the company as a volatile, single-asset entity dependent on the success of its lead drug, ivonescimab. Concentrated ownership and significant short interest create conditions for a potential short squeeze.
Recent price pullbacks do not change the investment thesis and may offer an attractive entry point. Two major clinical and regulatory catalysts are expected to determine the company's future performance.